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The Ocean, which is called the “mother of origin of life,” is also the source of structurally unique natural products that are mainly
accumulatedinlivingorganisms.Cyanobacteriaarephotosyntheticprokaryotesusedasfoodbyhumans.Theyareexcellentsource
ofvitaminsandproteinsvitalforlife.Severalofthesecompoundsshowpharmacologicalactivitiesandarehelpfulfortheinvention
and discovery of bioactive compounds, primarily for deadly diseases like cancer, acquired immunodeﬁciency syndrome (AIDS),
arthritis, and so forth, while other compounds have been developed as analgesics or to treat inﬂammation, and so forth. They
produce a large variety of bioactive compounds, including substances with anticancer and antiviral activity, UV protectants,
speciﬁc inhibitors of enzymes, and potent hepatotoxins and neurotoxins. Many cyanobacteria produce compounds with potent
biological activities. This paper aims to showcase the structural diversity of marine cyanobacterial secondary metabolites with a
comprehensive coverage of alkaloids and other applications of cyanobacteria.
1.Introduction
Cyanobacteria is a phylum of bacteria that obtain their en-
ergy through photosynthesis. The name “cyanobacteria”
comes from the color of the bacteria. Cyanobacteria are a
major and phylogenetically coherent group of Gram-ne-
gative prokaryotes possessing the unifying property of per-
forming oxygenic plantlike photosynthesis with autotrophy
as their dominant mode of nutrition [1]. However, in spite
of their typically aerobic photosynthetic nature, some of
the cyanobacterial species can grow in the dark on organic
substrates [2] and others under anaerobic conditions with
sulﬁde as electron donor for photosynthesis [3]. Certain
strains have the ability to ﬁx atmospheric dinitrogen into
organic nitrogen-containing compounds, so displaying the
simplest nutritional requirements of all microorganisms [4].
Cyanobacteria are also characterised by a great morpholog-
ical diversity, unicellular as well as ﬁlamentous species being
included with a cell volume ranging over more than ﬁve
orders of magnitude [5]. Representatives of the group have
been found, frequently in abundance, in most of the natural
illuminated environments examined so far, both aquatic and
terrestrial, including several types of extreme environments
[5]. This widespread distribution reﬂects a large variety of
species, covering a broad spectrum of physiological pro-
perties and tolerance to environmental stress [6]. Indeed,
several cyanobacterial strains such as chyoococcus sp (Figure
1(a)), phormidium sp (Figure 1(b)) possess, outside their
outer membrane, additional surface structures, mainly of
a polysaccharidic nature, that comprise a wide variety of
outermost investments diﬀering in thickness, consistency,
and appearance after staining. These structures, in spite of
the rather arbitrary terminology sometimes used, can be
referred to as three distinct types, namely, sheaths, capsules,
and slimes.
Over 300 nitrogen-containing secondary metabolites,
represented by diverse structural types, have been reported
from the prokaryotic marine cyanobacteria. A majority of
these metabolites are biologically active and are products
of either the nonribosomal polypeptide (NRP) or the mix-
ed polyketide-NRP biosynthetic pathways. Biomolecules of
the NRP and hybrid polyketide-NRP structural types are
important subsets of natural products utilized as therapeutic
agents.
These include the antibiotic vancomycin, the immuno-
suppressive agent cyclosporine, and the anticancer agent2 The Scientiﬁc World Journal
(a) (b)
Figure 1: Nomarski diﬀerential interference contrasts photomicrographs of sheathed cyanobacterial strains. (a) Chroococcus sp. (1000x); (b)
Phormidium sp. (1000x).
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Figure 2: Structure of dolastatin 10.
bleomycin [7]. Vancomycin is primarily eﬀective against
Gram-positive cocci. Staphylococcus aureus and Staphylo-
coccus epidermidis, including both methicillin-susceptible
(MSSA & MSSE) or resistant species (MRSA & MRSE), are
usually sensitive to vancomycin. Vancomycin is also eﬀective
against the anaerobes, diphtheroids, and clostridium species,
including C. diﬃcile,w h e r e a sB l e o m y c i ni sag l y c o p e p t i d e
antibioticproducedbythebacteriumStreptomycesverticillus.
It works by causing breaks in DNA as anticancer drug. The
drug is also used in the treatment of Hodgkin’s lymphoma,
squamous cell carcinomas, and testicular cancer, as well as
in the treatment of plantar warts and as a means of eﬀecting
pleurodesis. The discovery of these unique classes of natural
products from marine cyanobacteria represents an impor-
tant source of novel microbial secondary metabolites, in
addition to the actinomycetes and fungi, for drug discovery
eﬀorts.
1.1. Anticancer Drugs from Marine Cyanobacteria. An in-
creasing number of marine cyanobacterial compounds are
found to target tubulin or actin ﬁlaments in eukaryotic cells,
making them an attractive source of natural products as
anticancer agents [8]. Prominent molecules such as the anti-
microtubule agents, curacin A (Figure 3) and dolastatin 10
(Figure 2), have been in preclinical and/or clinical trials as
potential anticancer drugs [9].
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Figure 3: Structure of curacin A.
In addition, these molecules served as a drug leading
to the development of synthetic analogues, for example,
compound 4, TZT-1027 (Figure 4), ILX-651 (Figure 5), and
LU-103793 (7), usually with improved pharmacologicaland
pharmacokinetic properties for the treatment of diﬀerent
types of cancers. The antitumor activity of TZT-1027
(soblidotin) (Figure 4),asynthetic derivative ofdolastatin 10
(Figure 2), was found to be superior to existing anticancer
drugs, such as paclitaxel (Figure 6) and vincristine (Figure 7)
and is currently undergoing Phase I testing for treating solid
tumors [10].
The third generation dolastatin 15 analogue (Figure 5),
ILX-651(ortasidotin)(Figure 5),isanotherantitumoragent
currently undergoing Phase II trials after its successful run
in Phase I trials [11]. Pharmacological studies have also
showed the mechanistic novelty of certain molecules, such
as antillatoxin, in modifying the activity of Nav channels.The Scientiﬁc World Journal 3
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Figure 5: Structures of dolastatin-15, cemadotin, Tasidotin, and ILX651-C-carboxylate.
T h e s ec y a n o b a c t e r i a lt o x i n sa r es o u r c eo fv a l u a b l em o l e c u l a r
tools in functional characterization of Nav channels as well
as potential analgesics and neuroprotectants.
Thediscoveryoftiny,single-celledcyanobacteriaasubiq-
uitous and abundant components of the marine microbiota
has radically changed our view of the functioning and
composition of marine ecosystems. It is now clear that
the two genera Prochlorococcus and Synechococcus dominate
the photoautotrophic picoplankton over vast tracts of the
world’s oceans where they occupy a key position at the
base of the marine food web and contribute signiﬁcantly
to global primary productivity [12]. Cyanobacteria (blue-
green algae) are worldwide in distribution, occurring in
saline and nonsaline habitats of diverse ionic composition
[13]. However, more emphasis is now being placed on
the importance of various metabolic features as taxonomic
markers in cyanobacteria. Recently it has been suggested
that soluble organic compounds, accumulated as internal
osmotica in response to salinity stress, may provide a
major biochemical character which distinguishes marine4 The Scientiﬁc World Journal
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Figure 7: Structure of vincristine.
and freshwater forms [5]. Thus glucosylglycerol has been
considered to be “unique” to marine cyanobacteria [14],
while sucrose has been reported to accumulate in response
to osmotic stress in freshwater cyanobacteria [14].
1.2. Importance. Cyanobacteria in general and marine forms
in particular are one of the richest sources of known and
novel bioactive compounds including toxins with wide phar-
maceutical applications [15]. Anti-HIV activity of marine
cyanobacterial compounds from Lyngbya lagerheimii and
Phormidium tenue. A massive programme of screening of
extracts from the large culture collection of marine cyano-
bacteria for antiviral, antibacterial, antifungal, and immuno-
modulatoryactivitieshasresultedinrecoveryofacompound
frommarine Oscillatorialaete-virians BDU20801 thatshows
anti-Candida activity. An immunopotentiating compound
with male antifertility, without being toxic to other systems
in a mice model, was found in the extracts ofOscillatoria
willei BDU 130511 [16]. Medically important gamma lino-
lenic acid (GLA) is relatively rich in cyanobacteria, namely,
SpirulinaplatensisandArthrospirasp.whichiseasilyconvert-
ed into arachidonic acid in the human body and arachidonic
acid into prostaglandin E2 [17].
Prostaglandin E2 has lowering action on blood pressure
and the contracting function of smooth muscle and thus
plays an important role in lipid metabolism. The bioin-
formatic mining of cyanobacterial genomes has led to the
discovery of novel cyanobactins. Heterologous expression of
these gene clusters provided insights into the role of the
genes participating in the biosynthesis of cyanobactins and
facilitated the rational design of novel peptides.
1.3. Vitamins from Cyanobacteria. Some of the marine cy-
anobacteria appear to be potential sources for large-scale
production of vitamins of commercial interest such as vita-
mins of the B complex group and vitamin E [18]. The
carotenoids and phycobiliprotein pigments of cyanobacteria
have commercial value as natural food colouring agents, as
feed additives, as enhancers of the color of egg yolks, to
improve the health and fertility of cattle, as drugs, and in
the cosmetic industries. Some anti-HIV activity has been
observed with the compounds extracted from Lyngbya lage-
rhaimanii and Phormidium tenue [18].The Scientiﬁc World Journal 5
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Figure 8: Structures of mycobactins, yersiniabactin, and pyochelin.
1.4. Biotechnology and Applications of Marine Cyanobacteria.
The unicellular cyanobacterium Synechocystis sp. PCC6803
was the third prokaryote and ﬁrst photosynthetic organism
whose genome was completely sequenced.I tc o n t i n u e st ob e
an important model organism. The smallest genomes have
beenfoundinProchlorococcusspp.(1.7Mb)andthelargestin
Nostoc punctiforme (9Mb) [14]. Some cyanobacteria are sold
as food, notably Aphanizomenon ﬂos-aquae and Arthrospira
platensis (Spirulina)[ 14]. Recent research has suggested the
potential application of cyanobacteria to the generation of
clean and green energy via converting sunlight directly into
electricity. Currently eﬀorts are underway to commercialize
algae-basedfuelssuchasdiesel,gasoline,andjetfuel[19–24].
2.Secondary Metabolitesfrom
MarineCyanobacteria
2.1. Metabolic Themes and Building Blocks. There are cur-
rently some 300 marine cyanobacterial alkaloids. Of these,
128 marine cyanobacterial nitrogen-containing secondary
metabolites. The majority of these biomolecules were iso-
lated from the ﬁlamentous Order Nostocales, especially
members belonging to the genera Lyngbya, Oscillatoria, and
Symploca [20]. The locations of the collection sites were
mainly from the tropics, including Papua New Guinea and
the Paciﬁc islands, in particular Guam and Palau. The pre-
dominant metabolic theme of nitrogen-containing marine
cyanobacterial compounds is the occurrence of mixed pol-
yketide-nonribosomal polypeptide structural types.
These are molecules containing acetate or propionate
units as well as proteinogenic amino acids, forming as ei-
ther linear or cyclic lipopeptides as found in mycobactins,
Yersiniabactin and Pyochelin (Figure 8). The utilization of
acetate-derived units in the construction of these hybrid
compounds can be seen in several ways. Firstly, acetate-de-
rived fatty acid chain can be coupled through amide bonds
with a variety of functionalized amines in linear lipopeptides
(e.g. malyngamides, S (41)–W (45)).
Further modiﬁcations on the fatty acid chain, such
as methylation and halogenation, are common. Lipidation
throughamidebondsarealsocommoninanumberofoligo-
peptides, such as lyngbyabellin D and somamide. A Single
acetate unit or multiple ketides can also be utilized to extend
amino acids. For instance, a unit of acetate is used in the
extension of a variety of amino acids, such as Ala, Phe, Pro,
and Gly. The extension can either be linear or undergo cy-
clizationtoformcommonmoieties,suchaspyrrolinone ring
system in the jamaicamides [21, 22].6 The Scientiﬁc World Journal
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Figure 9: Structure of symplostatin 3.
Polyketide-derived moieties occurring as b-hydroxy or
amino acid residues are source of nonproteinogenic units in
the construction of lipopeptides, especially cyclic depsipep-
tides [22].
2.2. Nitrogen-Containing Lipids. Two new 2-alkypyridine
alkaloids, phormidinines A (10) and B (11), were reported
from an Okinawan collection of the marine cyanobacterium,
Phormidium sp.[ 21, 22]. The structures and absolute stere-
ochemistry of these compounds were determined based on
2D NMR spectra analysis and Mosher’s method, respective-
ly. A series of polychlorinated acetamides (12–16 and 19–
29) and its dechlorinated derivatives (17 and 18) have been
reported from Microcoleus lyngbyaceus and Lyngbyamajus-
cula/Schizothrix assemblage collected at Chuuk Island and
Fiji, respectively [23]. A majority of these unique molecu-
les are characterized by having terminal mono-, di-, or tri-
chlorinated functional groups. Other marine cyanobacterial
metabolites, for example, dysidenin-type compounds (e.g.,
62) and barbamide (61), having terminal di- and trichloro-
methyl groups were shown to derive from chlorination of
Leu, possibly via free radical mechanism. The biogenesis
of the taveuniamides, isolated from Fijian Lyngbya majus-
cula/Schizothrix assemblage, has been proposed to occur
either through the decarboxylation and methylation of an
octaketideprecursorortheC–Cbondformationbetweenthe
C-1 carboxyl carbon and C-2 of two tetraketide precursors
[23].
3. NaturalProductsfromMarineCyanobacteria
A number of highly potent cyanobacterial natural products
havebeenuncoveredaspotentialleadcompoundsforfurther
drugdevelopment,especiallyintheareaofanticanceragents.
An increasing number of lipopeptides, such as symplostatin
3( Figure 9), lyngbyastatin 3, hectochlorin (Figure 10), and
lyngbyabellins (114–116 and 118–123), have been reported
to target eukaryotic cytoskeletal macromolecules, such as
actin and microtubule ﬁlaments [24].
These are attractive biological features for the develop-
ment of potential anticancer drugs with speciﬁc cellular tar-
gets. Apratoxin A (126) is another potent cytotoxic com-
pound worthy of further biological investigation as anti-
cancer agent due to it mechanism of action in attenuating
the FGF (ﬁbroblast growth factor) signaling pathway [25].
Syntheticanaloguesbasedonthescaﬀoldsofthesecyanobac-
terial natural products can be developed for SAR studies as
well as lead optimization for drug development [26].
4. Intramolecular Modulation of Serine
ProteaseInhibitorActivityinaMarine
Cyanobacterium withAntifeedantProperties
One prevalent class found in marine and freshwater cyano-
bacteria is comprised of protease inhibitors with a cyclic
depsipeptide scaﬀold that contains a 3-amino-6-hydroxy-2-
piperidone (Ahp) moiety as a key feature for inhibition of
certain serine proteases [27]. Since many digestive enzymes
such as trypsin and chymotrypsin are serine proteases and
are inhibited by these compounds, these natural products
could function as digestion inhibitors [28]. Serine protease
inhibitors also cooccur with microcystins and are linked
to an enhanced toxin activity or thought to upregulate
biosynthetic genes [29]. The tropical sea urchin Diadema
antillarum,which is a cyanobacterium , produces a wide
array of serine protease inhibitors including lyngbyastatins
4–6 [30, 31], pompanopeptin A [32], and largamides D–
G[ 33]. The antifeedant activity may be a reﬂection of the
secondary metabolite content, known to be comprised of
many serine protease inhibitors. Further chemical and NMR
spectroscopic investigation led to isolate and structurally
characterize a new serine protease inhibitor 1that is formally
derivedfromanintramolecularcondensationoflargamideD
(2)( Figure 11)[ 33]. The cyclization resulted in diminished
activity, but to diﬀerent extents against two serine proteases
tested. This ﬁnding suggests that cyanobacteria can endoge-
nously modulate the activity of their protease inhibitors.
5. Cyanobacteria:A PotentialSource of
New Biologically ActiveSubstances
Cyanobacteria (blue-green algae) provide a potential source
of biologically active secondary metabolites [34]. Investiga-
tions over the last decades have identiﬁed compounds with
for instance cytotoxic, antifungal, antibacterial, or antiviral
activity.Hydrophilicandlipophilicextractsofcyanobacterial
strains, isolated from fresh and brackish water, and water
bloomswereinvestigatedfortheirantibioticactivitiesagainst
microorganisms both Gram negative and Gram positive.
Most of the isolated substances belong to groups of polyke-
tides, amides, alkaloids, and peptides [35].
The blue-green algae are among the oldest photoau-
totrophic organisms. Their cultivation without organic sub-
strates can be an economical advantage over other micro-
organisms. In view of the growing resistance of bacteriaThe Scientiﬁc World Journal 7
Cl Cl
O
S
N
HO
O
N
S
O
O O O
O
Figure 10: Structure of hectochlorin.
to common antibiotics, the search for new antimicrobially
active compounds has become increasingly important [36].
Screening programme was made which tested approximately
ﬁfty extracts from twelve diﬀerent cyanobacterial strains and
two water blooms against diﬀerent bacteria and one yeast.
The results of the study show the ability of cyanobacteria to
produce compounds with antimicrobial eﬀects [36].
5.1. Antimicrobial and Cytotoxic Assessment of Marine Cyano-
bacteria: Synechocystis and Synechococcus. Aqueous extracts
andorganicsolventextractsofisolatedmarinecyanobacteria
strains were tested for antimicrobial activity against a fun-
gus, Gram-positive and Gram-negative bacteria and for
cytotoxic activity against primary rat hepatocytes and HL-
60 cells [37]. Antimicrobial activity was based on the agar
diﬀusion assay. Cytotoxic activity was measured by apopto-
tic cell death scored by cell surface evaluation and nuclear
morphology [38]. A high percentage of apoptotic cells were
observed for HL-60 cells when treated with cyanobacterial
organic extracts [39]. Slight apoptotic eﬀects were observed
in primary rat hepatocytes when exposed to aqueous cyano-
bacterial extracts [40]. Marine Synechocystis and Synecho-
coccus extracts induce apoptosis in eukaryotic cells and
cause inhibition of Gram-positive bacteria. The diﬀerent ac-
tivity in diﬀerent extracts suggests diﬀerent compounds with
diﬀerent polarities [41].
6. Potential Commercial Development of
Insecticides,Algaecides, and
Herbicides from Cyanobacteria
Potential commercial development of cyanobacterial com-
pounds for nonbiomedical applications, particularly includ-
ingherbicides,algaecides,andinsecticidesposesapotentially
important opportunity to utilize the biological activity of
these compounds [26].
6.1. Insecticides. Fladmark et al. [42]. screened extracts from
76 isolates of cyanobacteria and found several of these
isolates produced compounds that were larvicidal to Aedes
aegypti.Thegreatestinhibition,however,wasassociatedwith
presence of the hepatotoxic microcystins and the neurotoxic
anatoxin-a. Humpage and Falconer [43] reported that, while
investigating cyanobacteria as a biofertilizer, several strains
were found to inhibit development of mosquito larvae,
and subsequently showed that methanolic extracts from an
isolate of Westiellopsis sp. were larvicidal to several species of
mosquito,includingrepresentativesofAedes aegypti (avector
forDengueFever),Anopheles stephensi (avectorformalaria),
andCulex tritaeniorhynchusandC.quinquefasciatus(vectors
of encephalitis). The use of genetically engineered cyanobac-
teria, speciﬁcally expressing the insecticidal proteins from
Bacillus thuringiensis to control mosquito larvae [44, 45].
Likewise,cyanobacteriathatproducenaturallyoccurringlar-
vicidal metabolites may eliminate the potential threats asso-
ciated with release of transgenic organisms [44, 45].
7. CyanobacterialCyclopeptidesas Lead
CompoundstoNovelTargetedCancerDrugs
Cyanobacterial cyclopeptides, including microcystins and
nodularins, are considered a health hazard to humans due
to the possible toxic eﬀects of high consumption [46].
From a pharmacological standpoint, microcystins are sta-
ble hydrophilic cyclic heptapeptides with a potential to
cause cellular damage following uptake via organic anion
transporting polypeptides (OATPs) [47]. Their intracellular
biological eﬀects involve inhibition of catalytic subunits
of protein phosphatase 1 (PP1) and PP2, and glutathione
depletion andgeneration of reactive oxygen species (ROS)
[48]. Interestingly, certain OATPs are prominently expressed
in cancers as compared to normal tissues, qualifying MC as
potential candidates for cancer drug development. In tar-
geted cancer therapy, cyanotoxins comprise a rich source
of natural cytotoxic compounds with a potential to target
cancers expressing speciﬁc uptake transporters [49]. Their
structure oﬀers opportunities for combinatorial engineering
to enhance the therapeutic index and resolve organ-speciﬁc
toxicity issues [50].
8. Conclusion
The fact that cyanobacteria are one of the richest sources
of known and novel bioactive compounds including toxins
with wide pharmaceutical applications is unquestionable.
Many compounds from cyanobacteria are useful for wel-
fare of mankind. Because of high discovery rate, research8 The Scientiﬁc World Journal
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should be done to unfold other hidden aspects of marine
cyanobacteria. An advantage of natural products research
on marine cyanobacteria is the high discovery rate (>95%)
of novel compounds as compared to other traditional mic-
robial sources. This is due largely to the unexplored nature
of this group of microalgae. One of the key areas to fur-
ther tap these microalgae for new chemical entities is the col-
lection of cyanobacterial strains from unexplored localities,
especially from Africa and Asia. In addition to the procure-
ment of marine cyanobacteria from unexplored locales, the
amenability of ﬁeld collected strains to laboratory culture is
an important factor in the drug discovery process.The Scientiﬁc World Journal 9
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